Selected Summaries
Stopping infliximab in crohn's disease: Still an ongoing STORI†
Laurent Peyrin-Biroulet MD, PhD,
Laurent Peyrin-Biroulet MD, PhD
Inserm, U954, Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
Search for more papers by this author Silvio Danese MD, PhD,
Silvio Danese MD, PhD
IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
Search for more papers by this author
Laurent Peyrin-Biroulet MD, PhD,
Laurent Peyrin-Biroulet MD, PhD
Inserm, U954, Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
Search for more papers by this author Silvio Danese MD, PhD,
Silvio Danese MD, PhD
IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
Search for more papers by this author
First published: 17 May 2012
No abstract is available for this article.
REFERENCES
- 1
Louis E,
Mary JY,
Vernier-Massouille G, et al.
Maintenance of remission among patients with Crohn's disease on anti-metabolite therapy after infliximab therapy is stopped.
Gastroenterology.
2012;
142:
63–70.
- 2
Colombel JF,
Sandborn WJ,
Reinisch W, et al.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
N Engl J Med.
2010;
362:
1383–1395.
- 3
Danese S,
Colombel JF,
Reinisch W, et al.
Review article: infliximab for Crohn's disease treatment—shifting therapeutic strategies after 10 years of clinical experience.
Aliment Pharmacol Ther.
2011;
33:
857–869.
- 4
Peyrin-Biroulet L,
Cieza A,
Sandborn WJ, et al.
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.
Gut.
2012;
61:
241–247.
- 5
Mariette X,
Matucci-Cerinic M,
Pavelka K, et al.
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.
Ann Rheum Dis.
2011;
70:
1895–1904.
- 6
Peyrin-Biroulet L,
Khosrotehrani K,
Carrat F, et al.
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Gastroenterology.
2011;
141:
1621–1628.
- 7
Kavanaugh A.
Economic issues with new rheumatologic therapeutics.
Curr Opin Rheumatol.
2007;
19:
272–276.
